This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Randomized Evaluation of COVID-19 Therapy | |
|---|---|
| Name | Randomized Evaluation of COVID-19 Therapy |
| Other names | RECOVERY |
| Start date | 2020 |
| Location | United Kingdom |
| Principal investigators | Peter Horby, Martin J. Landray |
| Sponsors | University of Oxford, National Institute for Health Research, NHS England |
| Phase | Adaptive platform trial |
| Conditions | COVID-19 pandemic |
| Interventions | Multiple repurposed therapies |
Randomized Evaluation of COVID-19 Therapy was a large adaptive platform trial initiated in 2020 to evaluate treatments for patients hospitalized with COVID‑19. Designed by investigators at the University of Oxford and funded by bodies including the National Institute for Health Research and Wellcome Trust, the trial enrolled tens of thousands of participants across England, Scotland, Wales, and Northern Ireland. The study produced high‑profile findings that influenced clinical guidance from organizations such as the World Health Organization, National Institutes of Health, and European Medicines Agency.
The trial was launched amid the global COVID-19 pandemic following early outbreaks in Wuhan, China and international spread through hubs like Milan, New York City, and Madrid. Investigators including Peter Horby and Martin J. Landray sought rapid evidence on repurposed drugs used in prior outbreaks such as Ebola and the 2009 flu pandemic. The platform drew on methodologies from trials like the SOLIDARITY trial and adaptive designs used in oncology and HIV/AIDS research. Funding and logistical support involved institutions such as the NHS England, UK Research and Innovation, Medical Research Council, Bill & Melinda Gates Foundation, and private partners.
RECOVERY was an open‑label, randomized, controlled, multicenter adaptive platform trial conducted in acute care settings across NHS hospitals. The protocol allowed multiple treatment arms to be added or stopped based on interim analyses overseen by an independent Data and Safety Monitoring Board and guided by statisticians familiar with group sequential methods used in large trials like the SOLIDARITY trial and PROTECT trial. Eligibility criteria targeted hospitalized adults with suspected or confirmed SARS‑CoV‑2 infection; baseline assessments included demographics, comorbidities such as diabetes mellitus, hypertension, and prior medications. The trial used centralized randomization with allocation concealment and pre‑specified primary and secondary endpoints modeled after outcomes in trials like RECOVERY-RS and referenced standards from the Consolidated Standards of Reporting Trials.
Arms included repurposed agents and standard care comparators: dexamethasone, hydroxychloroquine, lopinavir–ritonavir, azithromycin, tocilizumab, and others added adaptively such as convalescent plasma and monoclonal antibodies. Randomization ratios and factorial components resembled adaptive platform approaches used by trials like I-SPY and STAMPEDE. Investigators coordinated drug supply with regulatory bodies including the Medicines and Healthcare products Regulatory Agency and engaged manufacturers and academic collaborators for investigational arms. Enrollment targeted broad inclusion to maximize external validity and enable subgroup analyses by age, sex, and comorbid conditions like chronic obstructive pulmonary disease.
The primary outcome was 28‑day all‑cause mortality, with secondary outcomes including time to hospital discharge, progression to invasive mechanical ventilation, and need for renal replacement therapy. Sample size calculations and adaptive stopping rules used frequentist and Bayesian methods similar to those applied in large platform trials such as SOLIDARITY and oncology master protocols. Interim analyses by the independent monitoring board employed pre‑specified boundaries for efficacy and futility; multiplicity adjustments and subgroup tests followed guidance from authorities like the International Council for Harmonisation and standards exemplified in trials like PLATO.
Key findings included demonstration of mortality benefit with systemic dexamethasone in patients requiring oxygen or mechanical ventilation, leading to rapid changes in treatment guidance by the World Health Organization and national agencies such as Public Health England and the National Institutes of Health. Other arms—hydroxychloroquine and lopinavir–ritonavir—showed no mortality benefit and were discontinued; results influenced regulatory decisions by the European Medicines Agency and drug advisories from the Food and Drug Administration. Later adaptive comparisons evaluated immunomodulators such as tocilizumab and passive immunotherapies like convalescent plasma and neutralizing monoclonal antibodies, with mixed effect sizes across subgroups defined by biomarkers used in studies like ACTT‑1. Meta‑analyses and guideline panels including members from Infectious Diseases Society of America integrated RECOVERY data into systematic reviews.
Safety monitoring captured serious adverse events, secondary infections, hyperglycemia with corticosteroid use, and drug‑specific signals such as cardiac arrhythmias associated in other contexts with hydroxychloroquine and azithromycin. The independent Data and Safety Monitoring Board reviewed safety data and recommended stopping arms for harm or futility. Regulatory surveillance by agencies including the Medicines and Healthcare products Regulatory Agency and the Food and Drug Administration considered RECOVERY safety findings alongside pharmacovigilance databases like those maintained by the European Pharmacovigilance Risk Assessment Committee.
RECOVERY reshaped clinical practice and policymaking during the pandemic: adoption of dexamethasone into global treatment algorithms, de‑implementation of ineffective repurposed agents, and acceleration of trials for targeted therapies including monoclonal antibodies and antiviral agents. The trial influenced health technology assessment by bodies such as National Institute for Health and Care Excellence and procurement decisions by agencies like NHS Supply Chain and international partners including PAHO and Gavi. Its adaptive platform model informed subsequent preparedness strategies, ethics discussions in Nuffield Council on Bioethics reports, and collaborative frameworks among the World Health Organization, academic centers, and funders such as the Wellcome Trust.
Category:Clinical trials